JOP20200326A1 - مشتقات تترا هيدرو ثينوبيريدين بها استبدال بـ n واستخداماتها - Google Patents

مشتقات تترا هيدرو ثينوبيريدين بها استبدال بـ n واستخداماتها

Info

Publication number
JOP20200326A1
JOP20200326A1 JOP/2020/0326A JOP20200326A JOP20200326A1 JO P20200326 A1 JOP20200326 A1 JO P20200326A1 JO P20200326 A JOP20200326 A JO P20200326A JO P20200326 A1 JOP20200326 A1 JO P20200326A1
Authority
JO
Jordan
Prior art keywords
substituted
tetrahydrothienopyridine derivatives
derivatives
substituted tetrahydrothienopyridine
treating
Prior art date
Application number
JOP/2020/0326A
Other languages
English (en)
Inventor
Wei Lin Sandra Sim
Oliver Simon
Cyrille Kounde
Hui Quan Yeo
Bin Zou
Gang Wang
Fumiaki Yokokawa
Bryan Ks Yeung
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of JOP20200326A1 publication Critical patent/JOP20200326A1/ar

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/22—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms
    • C07C311/29—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

يتعلق الاختراع الحالي بمركب بالصيغة (I) أظهر أنه مفيداً لعلاج مرض ناتج عن إصابة فيروسية: حيث R1، R2، R3، A، L، m، n، p وq هي كما تم تعريفها في هذه الوثيقة.
JOP/2020/0326A 2018-06-19 2019-06-18 مشتقات تترا هيدرو ثينوبيريدين بها استبدال بـ n واستخداماتها JOP20200326A1 (ar)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862687068P 2018-06-19 2018-06-19
PCT/IB2019/055121 WO2019244047A1 (en) 2018-06-19 2019-06-18 N-substituted tetrahydrothienopyridine derivatives and uses thereof

Publications (1)

Publication Number Publication Date
JOP20200326A1 true JOP20200326A1 (ar) 2020-12-14

Family

ID=67841114

Family Applications (1)

Application Number Title Priority Date Filing Date
JOP/2020/0326A JOP20200326A1 (ar) 2018-06-19 2019-06-18 مشتقات تترا هيدرو ثينوبيريدين بها استبدال بـ n واستخداماتها

Country Status (23)

Country Link
US (1) US20220073535A1 (ar)
EP (2) EP3810613B1 (ar)
JP (1) JP7328260B2 (ar)
KR (1) KR20210022645A (ar)
CN (1) CN112313237A (ar)
AU (1) AU2019291488B2 (ar)
BR (1) BR112020025696A2 (ar)
CA (1) CA3100957A1 (ar)
CL (1) CL2020003248A1 (ar)
CR (1) CR20200618A (ar)
CU (1) CU20200100A7 (ar)
EA (1) EA202190046A1 (ar)
EC (1) ECSP20080995A (ar)
ES (1) ES2941946T3 (ar)
IL (1) IL279441B2 (ar)
JO (1) JOP20200326A1 (ar)
MA (1) MA52976A (ar)
MX (1) MX2020013852A (ar)
PE (1) PE20210097A1 (ar)
PH (1) PH12020552185A1 (ar)
SA (1) SA520420809B1 (ar)
SG (1) SG11202012625PA (ar)
WO (1) WO2019244047A1 (ar)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3663299B1 (en) * 2017-08-01 2023-03-08 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Bicyclic compound acting as ror gamma inhibitor
USD1006154S1 (en) * 2023-06-27 2023-11-28 Qiongfang Mao Cable crossover attachment

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5807A (en) 1848-09-26 Brake fob cabs
US498178A (en) 1893-05-23 William valentine leonard
US6344A (en) 1849-04-17 Driving-bobbin
US4656A (en) 1846-07-24 Improvement in potato-plows
US54472A (en) 1866-05-01 Improved blacking-brush
US8766A (en) 1852-02-24 Appabatus for lightening vessels
US5807876A (en) 1996-04-23 1998-09-15 Vertex Pharmaceuticals Incorporated Inhibitors of IMPDH enzyme
CN1116288C (zh) 1996-04-23 2003-07-30 沃泰克斯药物股份有限公司 用作肌苷－5'－一磷酸脱氢酶抑制剂的脲衍生物
DE69816280T2 (de) 1997-03-14 2004-05-27 Vertex Pharmaceuticals Inc., Cambridge Inhibitoren des impdh-enzyms
IL145475A0 (en) 1999-03-19 2002-06-30 Vertex Pharma Compounds that inhibit impdh enzyme and pharmaceutical compositions containing the same
US7138529B2 (en) * 2003-04-16 2006-11-21 Hoffmann-La Roche Inc. Substituted 3-cyanothiophene acetamides as glucagon receptor antagonists
US20130129677A1 (en) * 2009-02-27 2013-05-23 Siga Technologies, Inc. Thienopyridine Derivatives for the Treatment and Prevention of Dengue Virus Infections
CN104856991A (zh) * 2009-02-27 2015-08-26 西佳技术公司 用于治疗和预防登革热病毒感染的噻吩并吡啶衍生物
JP5701655B2 (ja) 2011-03-29 2015-04-15 奈良県 植物精油中のトロポロン類及び／又はフェノール類の金属錯体化方法
CN108689987A (zh) * 2017-04-05 2018-10-23 浙江海正药业股份有限公司 一种磺胺类衍生物及其制备方法和用途
PE20200342A1 (es) * 2017-05-22 2020-02-14 Janssen Pharmaceuticals Inc Derivados de indolina sustituidos como inhibidores de la replicacion virica de dengue
CN108191885B (zh) * 2018-01-29 2020-08-04 华东师范大学 一类哌啶并噻吩类小分子有机化合物及其应用

Also Published As

Publication number Publication date
EP3810613B1 (en) 2023-01-11
SA520420809B1 (ar) 2022-08-17
CU20200100A7 (es) 2021-08-06
MX2020013852A (es) 2021-05-27
EP4169925A3 (en) 2023-06-14
AU2019291488A1 (en) 2021-02-04
CL2020003248A1 (es) 2021-07-09
IL279441B2 (en) 2023-06-01
CA3100957A1 (en) 2019-12-26
ES2941946T3 (es) 2023-05-26
SG11202012625PA (en) 2021-01-28
ECSP20080995A (es) 2021-02-26
IL279441A (en) 2021-01-31
JP2021529159A (ja) 2021-10-28
EP3810613A1 (en) 2021-04-28
US20220073535A1 (en) 2022-03-10
CN112313237A (zh) 2021-02-02
AU2019291488B2 (en) 2022-02-24
CR20200618A (es) 2021-01-21
PE20210097A1 (es) 2021-01-12
JP7328260B2 (ja) 2023-08-16
BR112020025696A2 (pt) 2021-03-16
EP4169925A2 (en) 2023-04-26
EA202190046A1 (ru) 2021-03-24
KR20210022645A (ko) 2021-03-03
PH12020552185A1 (en) 2021-06-07
MA52976A (fr) 2021-04-28
WO2019244047A1 (en) 2019-12-26

Similar Documents

Publication Publication Date Title
PH12017501016A1 (en) Triazolopyrimidine compounds and uses thereof
NZ631726A (en) Therapeutic compounds for the treatment of viral infections
NZ728537A (en) Amide compounds for the treatment of hiv
NZ631762A (en) 5-membered heteroaryls and their use as antiviral agents
PH12017501326A1 (en) Tgf-� inhibitors
MX2022005160A (es) Oxisteroles y metodos de uso de los mismos.
MX2022005839A (es) Compuestos utiles como inhibidores de la proteina helios.
NZ631738A (en) (hetero) arylacetamide derivatives as antiretroviral agents
PH12019501198A1 (en) Tetracyclic heterocycle compounds useful as hiv integrase inhibitors
MX2017000330A (es) Derivado de piridona que tiene un grupo tetrahidropiranilmetilo.
CY1125004T1 (el) Ετεροαρυλο υποκατεστημενες βητα-υδροξυαιθυλαμινες για χρηση στη θεραπεια της υπεργλυκαιμιας
MY182353A (en) Novel sulfonimidoylpurinone compounds and derivatives for the treatment and prophylaxis of virus infection
PH12020552185A1 (en) N-substituted tetrahydrothienopyridine derivatives and uses thereof
EA201692189A1 (ru) Соединения фосфина золота (i) в качестве антибактериальных агентов
NZ746906A (en) Oxaborole esters and uses thereof
TN2021000025A1 (en) Novel heterocyclic amine derivative and pharmaceutical composition comprising same
MX2019011261A (es) Compuestos de isoxazol carboxamida y sus usos.
MX2021001804A (es) Compuestos de urea y composiciones como inhibidores de atpasa de smarca2/brm.
PH12021550646A1 (en) Isoxazole carboxamide compounds and uses thereof
MX2021016005A (es) Derivados de aminas terciarias y sus usos para tratar una infección vírica.
MX2021003481A (es) Compuesto heterociclico.
EA201591697A1 (ru) Гидрохлоридные соли антибиотического соединения
WO2020003272A8 (en) An improved process for the preparation of venetoclax
MX2018009943A (es) Proceso para la fabricacion de derivados de 3-piperazin-1-il-propi lamina.
GB201013509D0 (en) Compounds